

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner

Inter Partes Review No.: IPR2021-00880

U.S. Patent No. 9,669,069 B2
Filed: December 17, 2015
Issued: June 6, 2017
Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT
ANGIOGENIC EYE DISORDERS

**EXPERT DECLARATION OF DR. THOMAS A. ALBINI
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 9,669,069 B2**

TABLE OF CONTENTS

	<u>Page</u>
I. QUALIFICATIONS AND BACKGROUND.....	1
A. Education and Experience.....	1
B. Bases for Opinions and Materials Considered.....	4
C. Scope of Work.....	4
II. LEGAL STANDARDS.....	4
III. PERSON OF ORDINARY SKILL IN THE ART.....	9
IV. SUMMARY OF OPINIONS.....	11
V. THE '069 PATENT (Ex.1001).....	13
A. Claim Construction.....	15
VI. BACKGROUND.....	20
A. Vitreoretinal Disorders.....	20
1. Age-related macular degeneration (AMD).....	22
2. Diabetic retinopathy (DR).....	24
3. Diabetic macular edema (DME).....	24
4. Retinal vein occlusion (RVO).....	24
B. Angiogenesis and Vascular Endothelial Growth Factor (VEGF).....	25
C. VEGF Antagonists.....	25
D. VEGF Trap-Eye/Aflibercept.....	30
E. Regeneron's Press Releases and Clinical Trials.....	33
VII. SCOPE AND CONTENT OF THE PRIOR ART REFERENCES.....	42

TABLE OF CONTENTS
(continued)

	<u>Page</u>
A. Dixon (Ex.1006).....	42
B. Adis (Ex.1007).	47
C. Regeneron (28-April-2008) (Ex.1012).....	50
D. Heier-2009 (Ex.1020).....	51
E. Regeneron (30-April-2009) (Ex.1028).....	54
F. Mitchell (Ex.1030).	55
G. Lalwani (Ex.1035).....	57
H. '758 Patent (Ex.1010).	59
I. Dix (Ex.1033).....	60
VIII. UNPATENTABILITY OF THE '069 PATENT.	61
A. Claims 1 and 9-12 of the '069 Patent Are Anticipated by the CLEAR-IT-2 Disclosures in Either Heier-2009 (Ex.1020) or Dixon (Ex.1006).....	61
1. Claim 1 is anticipated by Heier-2009 and Dixon.	61
2. Dependent claims 9 and 10 are anticipated by Heier-2009 and Dixon.....	67
3. Dependent claim 11 is anticipated by Heier-2009 and Dixon.....	68
4. Dependent claim 12 is anticipated by Heier-2009 and Dixon.....	70
B. Claims 1 and 9-12 of the '069 Patent Are Anticipated by Regeneron (30-April-2009) (Ex.1028).....	71
1. Claim 1 of the '069 patent is anticipated by Regeneron (30-April-2009).....	71

TABLE OF CONTENTS
(continued)

	<u>Page</u>
2. Dependent claims 9 and 10 are anticipated by Regeneron (30-April-2009).....	75
3. Dependent claim 11 is anticipated by Regeneron (30-April-2009).....	77
4. Dependent claim 12 is anticipated by Regeneron (30-April-2009).....	78
C. Claims 1 and 8-12 of the '069 Patent Are Anticipated and Made Obvious by the VIEW1/VIEW2 Disclosures in Dixon.	78
1. Claim 1 of the '069 patent is anticipated by the VIEW1/VIEW2 disclosures.....	78
2. Claim 1 of the '069 patent is made obvious by the VIEW1/VIEW2 disclosures in Dixon.....	87
3. Dependent claim 8 is anticipated and made obvious by the VIEW1/VIEW2 disclosures.....	90
4. Dependent claims 9 and 10 of the '069 patent are anticipated and made obvious by the VIEW1/VIEW2 disclosures.....	91
5. Dependent claim 11 is anticipated and made obvious by the VIEW1/VIEW2 disclosures.....	92
6. Dependent claim 12 is anticipated and made obvious by the VIEW1/VIEW2 disclosures.....	93
D. Claims 1 and 8-12 of the '069 Patent Are Made Obvious by Heier-2009 (Ex.1020) in View of Mitchell (Ex.1030), or Alternatively in View of Dixon (Ex.1006), and if Necessary, in View of the '758 Patent (Ex.1010) or Dix (Ex.1033).....	94
1. Claim 1 of the '069 patent is obvious.....	94
2. Dependent claim 8 is obvious.....	103

TABLE OF CONTENTS
(continued)

	<u>Page</u>
3. Dependent claims 9 and 10 are obvious.	105
4. Dependent claim 11 is obvious.	105
5. Dependent claim 12 is obvious.	106
IX. SECONDARY CONSIDERATIONS.	107

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.